No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company that engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products. Its portfolio includes products for the cardio-cerebral vascular system, as well as segments for innovative medicine, generic medicine, and medical aesthetics which includes injectables, energy-based devices, and skincare solutions. The company operates primarily in the People's Republic of China, with some international presence.
www.sihuanpharm.comNo one on the platform currently holds 0460.HK.
No tracked institution reports a position in 0460.HK as of their last filing.
No one on the platform has traded 0460.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 8.0% | — | — | — | ||
| Rev. Growth % | 37.7% | 1.2% | ||||
| Profit Margin % | 6.9% | -16.3% | 0.4% | |||
| Free Cash Flow Margin % | -8.3% | -4.9% | 15.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.0B | +41.5% | $0.08 | $0.08–$0.08 | — | 1 |
| 2027 | $5.1B | +25.9% | $0.13 | $0.13–$0.13 | — | 1 |
| 2028 | $5.9B | +16.4% | $0.13 | $0.13–$0.13 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 0460.HKSihuan Pharmaceutical Holdings Group Ltd. | $0.73 | +2.08% | $6.6B | — |
| 0570.HKChina Traditional Chinese Medicine Holdings Co. Limited | $1.26 | -0.79% | $6.3B | — |
| 0719.HKShandong Xinhua Pharmaceutical Company Limited | $5.50 | +1.20% | $8.3B | — |
| 1681.HKConsun Pharmaceutical Group Limited | $13.28 | +1.84% | $11.1B | — |
| 2005.HKSSY Group Limited | $2.65 | +0.95% | $7.6B | — |
| 2186.HKLuye Pharma Group Ltd. | $1.79 | -0.56% | $7.2B | — |
| 2591.HKGuangzhou Innogen Pharmaceutl Grp Co Ltd | $4.04 | +1.38% | $1.8B | — |
Source: Financial Modeling Prep · peers by sector/industry